Treatment of childhood myoclonus with botulinum toxin type A

Journal of Child Neurology

Volumn 14, Issue 12, 1999, Pages 781-786

  Awaad, Yasser ^a,c   Tayem, Hassan ^a   Elgamal, Ahmad ^a   Coyne, Martha F ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b Bio logic Systems Corp   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; CARBIDOPA PLUS LEVODOPA; CYTOCHROME B; DANTROLENE; GLUTATHIONE PEROXIDASE; TRYPTOPHAN;

ADULT; ARTICLE; ASTROCYTOMA; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ENZYME DEFICIENCY; EVOKED RESPONSE; FEMALE; HUMAN; MALE; MYOCLONUS; NEGATIVE FEEDBACK; PRIORITY JOURNAL;

EID: 0033377858     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307389901401203     Document Type: Article

References (45)

1. Daube J: Reflexes and central motor control, in Clinical Neurophysiology, series 46. 1996, pp 346-350.
2. Selin C: The action of botulinum toxin at the neuromuscular junction. Med Biol 1981;59:11-20.
3. Borodic G, Pierce L, Ferrante R: Therapeutic botulinum toxin: Histologic effects and diffusion properties, in DasGupta BR (ed): Botulinum and Tetanus Neurotoxins. New York, Plenum Press, 1993; pp 623-645.
4. Brin MF, Blitzer A, Stewart C, et al: Disorders with excessive muscle contraction: Candidates for treatment with intramuscular botulinum toxin (BOTOX), in DasGupta BR (ed): Botulinum and Tetanus Neurotoxins. New York, Plenum Press, 1993, pp 559-576.
5. Jankovic J, Schwartz K, Clemence W, et al: A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996;11:250-256.
6. Moore P (ed): Handbook of Botulinum Toxin Treatment. Cambridge, MA, Blackwell Science, 1995.
7. Quirk JA, Sheean GL, Marsden CD, Lees AJ: Treatment of non-occupational limb and trunk dystonia with botulinum toxin. Mov Disord 1996;11:377-383.
8. Cony IS, Cosgrove AP, Walsh EG, et al: Botulinum toxin A in the hemiplegic upper limb: A double blind trial. Dev Med Child Neurol 1997;39:185-193.
9. Burbaud P, Wiart L, Dubos JL, et al: A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-269.
10. Koskiniemi M, Donner M, Majuri H, et al: Progressive myoclonus epilepsy. A clinical and histopathological study. Acta Neurol Scand 1974;50:307-332.
11. Van Bogaert L, Radermecker J, Titeca J: Les syndromes myocloniques. Folia Psychiatr Neuro Neurochirug Neerl 1950;53: 650-690.
12. Fukahara N, Tokiguchi S, Shirakawa K, Tsubaki T: Myoclonus epilepsy associated with ragged-red fibers (mitochondrial abnormalities): Disease entity or a syndrome? J Neurol Sci 1980;47: 117-133.
13. Richardson JC, Rewcastle NB, de Lean J: Hypoxic myoclonus: Clinical and pathological observations, in Rose FC (ed): Physiological Aspects of Clinical Neurology. Oxford, Blackwell Scientific 1977, pp 231-245.
14. Oka H, Matsushima M, Ando K, Hoshizaki H: Intention myoclonus in acute leukaemia. Brain 1972;95:395-398.
15. Bradshaw J: A study of myoclonus. Brain 1954;138-157.
16. Symonds C: Myoclonus. Med J Aust 1954;1:765-768.
17. Halliday AM: The electrophysiological study of myoclonus in man. Brain 1967;90:241-284.
18. Lance JW, Adams RD: The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 1963;86: 111-136.
19. Dawson GD: Investigations on a patient subject to myoclonic seizures after sensory stimulation. J Neurol Neurosurg Psychiatry 1947;10:141-162.
20. Halliday AM: Cerebral evoked potentials in familial progressive myoclonic epilepsy. JR Coll Physicians Lond 1967;1:123-134.
21. Shibasaki H, Yamashita Y, Kuroiwa Y: Electroencephalographic studies of myoclonus. Brain 1978;101:447-460.
22. Hallett M, Chadwick D, Marsden CD: Cortical reflex myoclonus. Neurology 1979;29:1107-1125.
23. Hallett M, Chadwick D, Adam J, et al: Reticular reflex myoclonus: A physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry 1977;40:253-264.
24. Bickford RG, Jacobson JL, Cody DTR: Nature of average evoked potentials to sound and other stimuli in man. Ann NY Acad Sci 1964;112:204-223.
25. Lance JW: Concluding remarks, in Fahn S, Marsden CD, Van Woert MH (eds): Advances in Neurology, vol 43, Myoclonus. New York, Raven Press, 1986.
26. Noad KB, Lance JW: Familial myoclonic epilepsy and its association with cerebellar disturbance. Brain 1960;83:618-630.
27. Rosen AD, Berenyi KJ, Laurenceau V: Intention myoclonus -diazepam and phenobarbital treatment. JAMA 1969;209:772-773.
28. Elridge R, Iivanainen M, Stern R, Koerber T: Baltic myoclonus epilepsy: A treatable, inherited disorder distinct from Lafora's disease, Abstract. Neurology (NY) 1981;31:67-68.
29. Lhermitte F, Marteau R, Degos CF: Analyse pharmacologique d'un nouveau cas de myoclonies d'intention et d'action post-anoxiques. Rev Neurol (Paris) 1972;126:107-114.
30. Chadwick D, Hallett M, Harris R, et al: Clinical, biochemical and physiological factors distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan plus a monoamine oxidase inhibitor and clonazepam. Brain 1977;100:455-487.
31. Van Woert MH, Sethy VH: Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK486. Neurology 1975;25:135-140.
32. Bourdouresques J, Roger J, Khalil R, et al: A propos de 2 observations de syndrome de Lance et Adams. Effet thérapeutique du Ro-05-4023. Rev Neurol (Paris) 1971;125:306-307.
33. Goldberg MA, Dorman JD: Intention myoclonus: Successful treatment with clonazepam. Neurology 1976;26:24-26.
34. Rollinson RD, Gilligan BS: Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate. Arch Neurol 1979;36:44-45.
35. Sotaniemi K: Valproic acid in the treatment of nonepileptic myoclonus. Report of three cases. Arch Neurol 1982;39:448-449.
36. Lance JW, Anthony M: The anticonvulsant action of sodium valproate (Epilim) in 100 patients with various forms of epilepsy. Med J Aust 1977;1:911-915.
37. Somerville ER, Olanow W: Valproic acid. Treatment of myoclonus in dyssynergia cerebellaris myoclonica. Arch Neurol. 1982;39: 527-528.
38. Lance JW, Anthony M: Sodium valproate and clonazepam in the treatment of intractable epilepsy. Arch Neurol 1977;34:14-17.
39. Pranzatelli MR: Antidyskinetic drug therapy for pediatric movement disorders. J Child Neurol 1996;11:355-369.
40. Hoehn MM, Cherington M: Spinal myoclonus. Neurology 1977;27: 942-946.
41. Menon MK: Possible value of baclofen in myoclonus. JAMA 1980; 244:239-240.
42. Awaad Y, Fish I: Baclofen in the treatment of polymyoclonus in a patient with Unverricht-Lundborg disease. J Child Neurol 1995; 10:68-70.
43. Awaad Y, Sansaricq C, Moroney J, et al: Baclofen in the treatment of polymyoclonus and ataxia in a patient with homocystinuria. J Child Neurol 1995;10:294-296.
44. Polo KB, Jabbari B: Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord 1994;9:233-235.
45. Shahani BT (ed): Electromyography in CNS Disorders. Boston, Butterworths, 1984.